Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the five ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $9.40.
A number of research analysts have commented on AMRX shares. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price objective on the stock in a research report on Friday, September 6th. Barclays increased their price objective on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a research report on Tuesday, August 13th. Finally, Truist Financial increased their price target on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday.
Get Our Latest Analysis on AMRX
Amneal Pharmaceuticals Stock Up 1.2 %
Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last announced its quarterly earnings data on Friday, August 9th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.04. The firm had revenue of $701.78 million for the quarter, compared to analyst estimates of $657.43 million. Amneal Pharmaceuticals had a positive return on equity of 1,235.03% and a negative net margin of 6.72%. As a group, sell-side analysts forecast that Amneal Pharmaceuticals will post 0.52 earnings per share for the current fiscal year.
Institutional Trading of Amneal Pharmaceuticals
Several hedge funds have recently added to or reduced their stakes in AMRX. Vanguard Group Inc. raised its stake in shares of Amneal Pharmaceuticals by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 13,728,233 shares of the company’s stock valued at $83,193,000 after purchasing an additional 85,846 shares during the period. Rubric Capital Management LP grew its holdings in shares of Amneal Pharmaceuticals by 12.4% in the 2nd quarter. Rubric Capital Management LP now owns 10,721,778 shares of the company’s stock valued at $68,083,000 after acquiring an additional 1,179,830 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Amneal Pharmaceuticals by 17.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 4,283,928 shares of the company’s stock valued at $27,205,000 after acquiring an additional 641,405 shares in the last quarter. Nantahala Capital Management LLC grew its holdings in shares of Amneal Pharmaceuticals by 1.9% in the 2nd quarter. Nantahala Capital Management LLC now owns 2,669,943 shares of the company’s stock valued at $16,954,000 after acquiring an additional 50,000 shares in the last quarter. Finally, BlackBarn Capital Partners LP grew its holdings in shares of Amneal Pharmaceuticals by 41.5% in the 2nd quarter. BlackBarn Capital Partners LP now owns 2,000,000 shares of the company’s stock valued at $12,700,000 after acquiring an additional 586,703 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.
Amneal Pharmaceuticals Company Profile
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.
Further Reading
- Five stocks we like better than Amneal Pharmaceuticals
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- Bank Stocks – Best Bank Stocks to Invest In
- MarketBeat Week in Review – 9/30 – 10/4
- How to Start Investing in Real Estate
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.